Blood Level Omega-3 Fatty Acids as Risk Determinant Molecular Biomarker for Prostate Cancer
Table 2
(a) Blood level omega-3 polyunsaturated fatty acids versus total prostate risk random effect analysis model. (b) Blood level omega-3 polyunsaturated fatty acids versus total prostate risk subgroup analysis model (nested case control versus case control).
(a)
Groups
Effect estimates and 95% confidence interval
Publication bias
Omega-3 derivatives
Number of study
value
df
value
Point estimates
Lower limit
Upper limit
value
Begg
Egger
ALA
10
11.548
9
0.240
22.065
1.188
0.955
1.477
0.123
0.283
0.502
DHA
11
18.991
10
0.040
47.343
0.876
0.685
1.119
0.290
0.436
0.239
DHA‡
10
14.450
9
0.107
37.716
0.935
0.733
1.194
0.591
0.211
0.127
DPA
6
3.883
5
0.566
0.000
0.756
0.599
0.955
0.019
1.000
0.540
EPA
11
14.741
10
0.142
32.162
0.971
0.784
1.204
0.792
0.533
0.671
EPA‡
10
8.656
9
0.470
0.000
1.070
0.898
1.275
0.446
0.211
0.502
(DHA + DPA + EPA)*
32.676
25
0.139
23.492
0.942
0.834
1.064
0.336
(DHA + EPA)*
23.410
19
0.220
18.840
1.022
0.887
1.179
0.760
Total omega-3*
47.526
35
0.077
26.356
0.995
0.895
1.107
0.929
(b)
Groups
Effect estimates and 95% confidence interval
Publication bias
Omega-3 derivatives
Number of study
value
df
value
Point estimates
Lower limit
Upper limit
value
Begg
Egger
ALA
10
11.548
9
0.240
22.065
1.188
0.955
1.477
0.123
0.283
0.502
Case control
5
6.893
4
0.142
41.971
1.237
0.735
2.083
0.423
Nested case control
5
4.614
4
0.329
13.300
1.191
0.948
1.496
0.132
DHA
11
18.991
10
0.040
47.343
0.876
0.685
1.119
0.290
0.436
0.239
Case control
6
5.433
5
0.365
7.972
0.769
0.558
1.060
0.109
Nested case control
5
11.213
4
0.024
64.327
0.942
0.670
1.325
0.733
DPA
6
3.883
5
0.566
0.000
0.756
0.599
0.955
0.019
1.000
0.540
Case control
2
1.126
1
0.289
11.180
0.620
0.278
1.382
0.243
Nested case control
4
2.433
3
0.488
0.000
0.773
0.605
0.988
0.040
EPA
11
14.741
10
0.142
32.162
0.971
0.784
1.204
0.792
0.533
0.671
Case control
6
4.603
5
0.466
0.000
0.851
0.634
1.143
0.285
Nested case control
5
8.661
4
0.070
53.818
1.028
0.757
1.396
0.859
Interstudy heterogeneity was tested by Cochrane’s (Chi2) at a significance level of and quantified by , where % is considered to be evidence of substantial heterogeneity and ≥75%, considerable heterogeneity. ‡Interstudy variation adjusted (heterogeneous study removed from the pool of effect estimates).
*Generated from adjusted total effect estimates from each PUFA random effect analysis.
